Comparative Pharmacology
Head-to-head clinical analysis: CELEBREX versus ELYXYB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELEBREX versus ELYXYB.
CELEBREX vs ELYXYB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-2 (COX-2) selectively, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever. It does not significantly inhibit COX-1 at therapeutic concentrations.
Topical analgesic; inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in peripheral tissues.
100-200 mg orally twice daily; for acute pain or primary dysmenorrhea, 400 mg initially followed by 200 mg twice daily as needed.
Topical application of 5.6 g (one unit dose tube) to the target area of the forehead and temple using the hand-held applicator, applied only once per migraine attack. Maximum dose: 5.6 g per day.
None Documented
None Documented
Terminal elimination half-life is approximately 11 hours (range 8-12 hours) in healthy adults; in elderly patients (≥65 years), half-life is prolonged to ~18 hours; in patients with mild-to-moderate hepatic impairment, half-life increased by 2-fold.
Terminal elimination half-life is approximately 2-3 hours in healthy adults. No clinically relevant accumulation with repeated dosing at recommended intervals.
Primarily hepatic metabolism via CYP2C9; approximately 27% of dose excreted in urine as unchanged drug and metabolites, with about 3% as unchanged celecoxib; 57-70% excreted in feces as metabolites.
Primarily renal excretion of metabolites; 70-80% of dose recovered in urine as glucuronide conjugates, with <1% as unchanged drug. Biliary/fecal excretion accounts for approximately 10-20%.
Category C
Category C
NSAID (COX-2 Inhibitor)
NSAID (COX-2 Inhibitor)